Which cardiac patients with nausea should not receive domperidone in primary care?
Avoid domperidone in primary care if the cardiac patient has any known QT prolongation, history of ventricular arrhythmia, significant bradycardia, or structural/underlying cardiac disease such as heart failure or clinically important ischemic disease. Do not use it if they are also taking other QT-prolonging or potent
Which ASCVD phenotypes are best suited for inclisiran after maximally tolerated statin and ezetimibe?
After maximally tolerated statin + ezetimibe, inclisiran is best suited to very-high-risk ASCVD patients who remain above LDL-C goal, especially those with recurrent/polyvascular disease, recent ACS, familial hypercholesterolemia phenotype, or patients in whom long-term adherence to frequent self-injection is a barrier
When should a mild early eGFR dip after dapagliflozin be observed rather than labelled intolerance?
A small, early fall in eGFR after starting dapagliflozin is usually an expected hemodynamic effect, not intolerance, if the patient is clinically well, the creatinine rise is limited, and renal function stabilizes on repeat testing. Product information and renal-protective trial data support ongoing use in appropriate
Which anatomic and clinical factors should outweigh symptom burden when choosing CABG over PCI?
When deciding CABG over PCI, anatomic and prognostic factors should outweigh symptom burden whenever the revascularization choice is being driven by survival, MI reduction, durability of complete revascularization, or future-event prevention, rather than simply angina relief. In practice, CABG is generally favored when
Should LDL-C intensification proceed before blood pressure is fully controlled in a high-risk patient?
Yes — in a high-risk patient, LDL-C intensification should generally proceed even if blood pressure is not yet fully controlled, provided there is no immediate hypertensive emergency or other instability. Hypertension and dyslipidemia are additive/synergistic ASCVD risk factors, and Philippine guidance treats both as p
